The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck
Published in
International Journal of Radiation Oncology, Biology, Physics, October 2019
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2020.
All research outputs
#23,851,231
of 34,089,221 outputs
Outputs from International Journal of Radiation Oncology, Biology, Physics
#11,599
of 15,419 outputs
Outputs of similar age
#258,322
of 393,831 outputs
Outputs of similar age from International Journal of Radiation Oncology, Biology, Physics
#149
of 283 outputs
Altmetric has tracked 34,089,221 research outputs across all sources so far. This one is in the 28th percentile – i.e., 28% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,419 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,831 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 283 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
